ENSIGN PHARMACEUTICAL, INC.

Omaha, NE · Biotech · Private

HPMA copolymer-dexamethasone thermoresponsive hydrogel (ProGel) for intra-articular injection delivering sustained dexamethasone release to osteoarthritis joints

Grants
$3.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · ProGel Technology for Better Management of Osteoarthritis Pain$252,131
Federal grantDepartment of Health and Human Services · Phase II · ProGel Technology for Better Management of Osteoarthritis Pain$840,440
Federal grantDepartment of Health and Human Services · Phase II · ProGel Technology for Better Management of Osteoarthritis Pain$1,680,880
Federal grantDepartment of Health and Human Services · Phase II · ProGel Technology for Better Management of Osteoarthritis Pain$840,440
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1152SERION, INC.——
1153THERASOURCE, LLC——
1154LOHOCLA RESEARCH CORPORATION——
1155ENSIGN PHARMACEUTICAL, INC.——
1156ALLIANCE DISCOVERY, INC.——
1157PALENA THERAPEUTICS, INC.——
1158ASTRAEA THERAPEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.